Welcome to our dedicated page for Fate Therapeutic SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fate Therapeutics files SEC reports that document its clinical-stage biopharmaceutical business and its iPSC-derived cellular immunotherapy pipeline for cancer and autoimmune diseases. Current reports furnish operating results and business updates, including disclosures on FT819, FT836 and other off-the-shelf CAR T-cell programs, FDA-related development matters, clinical presentations, and costs associated with restructuring actions.
Proxy and current-report filings cover board and compensation governance, equity-plan matters, Regulation FD disclosures, and capital-structure details for FATE common stock listed on the Nasdaq Global Market. The filings also record material events affecting operations and public-company reporting obligations.
Fate Therapeutics officer Cindy Tahl reported an open-market sale of 25,590 shares of common stock at a weighted average price of $1.879 per share. The company states the shares were sold solely to cover tax withholding on the vesting of 50,000 performance-based RSUs granted on July 29, 2024, under a pre-arranged sell-to-cover election rather than at her discretion.
After these tax-related sales, Tahl directly holds 628,155 shares of Fate Therapeutics common stock.
Fate Therapeutics President and CEO Bahram Valamehr reported an automatic sale of 28,946 shares of Common Stock. The shares were sold on open market on May 20, 2026 at a weighted average price of $1.8822 per share to cover tax withholding obligations tied to the vesting of 50,000 performance-based RSUs granted on July 29, 2024. The transactions were executed pursuant to a prior irrevocable sell-to-cover election and were not made at his discretion. Following these sales, Valamehr continues to hold 635,762 shares directly.
Fate Therapeutics reported a Q1 2026 net loss of $31.2 million, improving from a $37.6 million loss a year earlier, as it continued investing in its off-the-shelf iPSC-derived cell therapy pipeline. Collaboration revenue was $1.3 million compared with $1.6 million in Q1 2025, all from research and preclinical services under its Ono partnership.
Research and development expenses were $24.7 million versus $29.1 million, and general and administrative expenses were $9.6 million versus $13.8 million, reflecting ongoing cost reductions. Cash, cash equivalents and short‑term investments totaled $174.8 million as of March 31, 2026, and management believes this will fund operations for at least twelve months. The company remains a clinical‑stage biopharmaceutical business with an accumulated deficit of about $1.6 billion and no product sales to date.
Fate Therapeutics reported first quarter 2026 results and highlighted major advances in its iPSC-derived cell therapy pipeline. Collaboration revenue was $1.3 million, while total operating expenses fell to $34.3 million, about a 20% year-over-year reduction, leading to a narrower net loss of $31.2 million (or $0.26 per share). The company ended March 31, 2026 with $174.8 million in cash, cash equivalents and investments, which it expects to fund operations into 2028.
Clinically, FT819, an off-the-shelf CD19 CAR T-cell for autoimmune disease, advanced with FDA selection into the CMC Development and Readiness Pilot program and continued enrollment in a Phase 1 trial across multiple autoimmune indications. A Phase 2 potentially registrational lupus nephritis study of FT819 is planned to start dosing in the second half of 2026. Next-generation programs FT839 and FT836 also progressed, with FT839 nearing IND submission for a Phase 1 autoimmune basket trial and FT836 showing early safety in a Phase 1 solid tumor study.
Fate Therapeutics officer Cindy Tahl exercised stock options to acquire a total of 166,664 shares of common stock on May 6, 2026. She exercised 44,444 options at $1.05 per share and 122,220 options at $1.32 per share, with no open-market sales reported. Following these transactions, she directly holds 609,301 shares of common stock. The options exercised relate to grants that vest in 36 equal monthly installments starting January 1, 2025 and January 1, 2026, becoming fully vested in 2028 and 2029, subject to her continued service.
Fate Therapeutics director Robert S. Epstein exercised stock options to acquire 25,000 shares of Common Stock at $1.69 per share. The options related to shares that vested on the date of the company’s 2017 Annual Meeting of Stockholders. After the transaction, he directly holds 36,331 Fate Therapeutics shares.
FATE Therapeutics director William H. Rastetter exercised stock options to acquire 25,000 shares of Common Stock at $1.69 per share. Following the exercise, he holds 36,331 Common shares directly. In addition, 459,272 shares are held indirectly by The Investment 2002 Trust and 146,821 shares are held indirectly by The Rastetter Family Trust, where he serves in trustee roles.